Pinealon

Pinealon is the synthetic Glu-Asp-Arg (EDR) tripeptide developed by Vladimir Khavinson and colleagues at the St Petersburg Institute of Bioregulation and Gerontology as part of their short-peptide bioregulator program. It is supplied here as a lyophilized research-use compound.

Khavinson and colleagues propose that short peptides like EDR enter cells and interact with DNA promoter regions to modulate transcription of specific genes. The bulk of the published data supporting this mechanism originates from Khavinson-affiliated groups; independent replication outside their network is limited, which is important context when interpreting the literature.

In cultured cortical neurons and rodent models, Pinealon / EDR has been reported to reduce reactive oxygen species accumulation under oxidative stress, decrease necrotic cell death in hypoxia/ischemia conditions, and alter expression of apoptosis- and antioxidant-related genes. All such reports are preclinical and in vitro / in vivo animal data.

Pinealon is the tripeptide L-glutamyl-L-aspartyl-L-arginine (Glu-Asp-Arg, EDR), molecular formula C15H26N6O8, molecular weight approximately 418.4 Da, CAS 175175-23-2.

No. Pinealon has no FDA approval. It is supplied strictly as a research-use compound for in vitro and preclinical investigation. It is not intended for diagnosis, prevention, treatment or any use in humans or animals outside controlled research settings.

Store lyophilized powder at -20 C for long-term stability and protect from light. Once reconstituted in sterile water, refrigerate at 2-8 C and use within 14 days. Avoid repeated freeze-thaw cycles.